Penile erection and cardiac risk: Pathophysiologic and pharmacologic mechanisms

American Journal of Cardiology

Volumn 86, Issue 2 SUPPL. 1, 2000, Pages 23-26

  Andersson, Karl Erik ^a   Stief, Christian ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHENTOLAMINE; SILDENAFIL;

CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY ARTERY DISEASE; ERECTILE DYSFUNCTION; HEART MUSCLE; HEMODYNAMICS; HYPERTENSION; HYPOTENSION; PENIS ERECTION; PRIORITY JOURNAL; TACHYCARDIA;

EID: 0034691699     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00887-0     Document Type: Conference Paper

References (40)

1. Andersson K.-E., Wagner G. Physiology of penile erection. Physiol Rev. 75:1995;191-236.
2. Andersson K-E, Hedlund P, Alm P. Identification and localization of sympathetic pathways to and adrenergic innervation of the penis. Int J Impot Res 2000; in press.
3. Hedlund P., Alm P., Ekström P., Fahrenkrug J., Hannibal J., Hedlund H., Larsson B., Andersson K.-E. Pituitary adenylate cyclase-activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum. Br J Pharmacol. 116:1995;2258-2266.
4. Burnett A.L. Nitric oxide in the penis physiology and pathology . J Urol. 157:1997;320-324.
5. Bohlen J.G., Held J.P., Sanderson M.O., Patterson R.P. Heart rate, rate-pressure product, and oxygen uptake during four sexual activities. Arch Intern Med. 144:1984;1745-1748.
6. Becker A.J., Ückert S., Stief C.G., Truss M.C., Machtens S., Scheller F., Knapp W.H., Hartmann U., Jonas U. Plasma levels of cavernous and systemic norepinephrine and epinephrine in men during different phases of penile erection. Akt Urologie Urologe [A]. 38:1999;S124.
7. Andersson K.-E., Steers W.D. The pharmacological basis of sexual therapeutics. Morales A. Erectile Dysfunction. Issues in Current Pharmacotherapy. 1998;97-124 Martin Dunitz Ltd, London.
8. 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine. J Urol. 153:1995;222-227.
9. 1-adrenergic receptor subtypes in human corpus cavernous tissue and in cultured trabecular smooth muscle cells. Receptor. 5:1996;145-157.
10. Davis B, Chapple C, Chess-Williams R. The a1 L-adrenoceptor mediates contraction in human erectile tissue. (Abstr.) Eur Urol 1999;35(suppl 2):102.
11. Traish A.M., Moreland R.B., Huang Y.H., Goldstein I. Expression of functional alpha2-adrenergic receptor subtypes in human corpus cavernosum and in cultured trabecular smooth muscle cells. Recept Signal Transduct. 7:1997;55-67.
12. 2-adrenoceptors in the human penis: affinities of trazodone. (Abstr.) Eur Urol 1999;35(suppl 2):102.
13. Simonsen U., Prieto D., Hernandez M., Saenz de Tejada I., García-Sacristán A. Prejunctional alpha 2-adrenoceptors inhibit nitrergic neurotransmission in horse penile resistance arteries. J Urol. 157:1997;2356-2360.
14. Muramatsu I., Ohmura T., Hashimoto S., Oshita M. Functional subclassification of vascular α1-adrenoceptors. Pharmacol Commun. 6:1995;23-28.
15. Hattori Y., Kanno M. Role of alpha1-adrenoceptor subtypes in production of the positive inotropic effects in mammalian myocardium implications for the alpha1-adrenoceptor subtype distribution . Life Sci. 62:1998;1449-1453.
16. Baumgart D., Haude M., Gorge G., Liu F., Ge J., Grosse-Eggebrecht C., Erbel R., Heusch G. Augmented alpha-adrenergic constriction of atherosclerotic human coronary arteries. Circulation. 99:1999;2090-2097.
17. Traish A., Gupta S., Gallant C., Huang Y.H., Goldstein I. Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms. Int J Impot Res. 10:1998;215-223.
18. Hoffman B.B., Lefkowitz R.J. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. Harman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. Goodman and Gilman′s The Pharmacological Basis of Therapeutics. 9th edition. 1996;199-248 McGraw-Hill, New York.
19. Gould L.A., Reddy C.V. Oral therapy with phentolamine in chronic congestive heart failure. Chest. 75:1979;487-491.
20. Schreiber R., Maier P.T., Gunnar R.M., Loeb H.S. Hemodynamic improvement following single dose of oral phentolamine administration in patients with chronic low output cardiac failure . Chest. 76:1979;571-575.
21. Wyllie M.G., Andersson K.-E. Orally actve agents the potential of alpha-adrenoceptor antagonists . Carson C., Kirby R., Goldstein I. Isis Textbook of Erectile Dysfunction. 1999;317-322 Medical Media, Oxford.
22. Beavo J.A. Cyclic nucleotide phosphodiesterases functional implications of mutiple isoforms . Physiol Rev. 75:1995;725-748.
23. Polson J.B., Strada S.J. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 36:1996;403-427.
24. Dousa T.P. Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int. 55:1999;29-62.
25. Taher A, Stief CG, Raida M, Jonas U, Forssmann WG. Cyclic nucleotide phosphodiesterase activity in human cavernous smooth muscle and the effect of various selective inhibitors. (Abstr.) Int J Impot Res 1992;4(suppl 2):11.
26. Stief C.G., Taher A., Truss M., Ückert S., Meyer M., Schulz-Knappe P., Forssmann W.F., Jonas U. Die Phosphodiesterase-Isoenzyme des humanen corpus cavernosum penis und deren funktionelle Bedeutung. Akt Urol. 26:(suppl I):1995;58-61.
27. Stief CG, Küthe A, Ückert S, Broderick GA, Jonas U. Phosphodiesterases in human cavernous smooth muscle: expression and possible clinical significance. Dallas, TX: American Urological Association Postgraduate Course: 1999;in press.
28. Ballard S.A., Gingell C.J., Tang K., Turner L.A., Price M.E., Naylor A.M. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 159:1998;2164-2171.
29. Ballard SA, Turner LA, Naylor AM. Sildenafil, a potent selective inhibitor of type 5 phosphodiesterase enhances nitric oxide-dependent relaxation of rabbit corpus cavernosum. (Abstr.) Br J Pharmacol 1996;118:153.
30. Küthe A, Stief CG, Mägert H-J, Ückert S, Forssmann W-G, Jonas U. Molecular biological characterisation of phosphodiesterases 3 and 5 in human corpus cavernosum penis (Abstr.) Eur Urol 1999;35(suppl 2):102.
31. Stief C.G., Ückert S., Becker A.J., Truss M.C., Jonas U. The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo. J Urol. 159:1998;1390-1394.
32. Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., Osterloh I.H., Gingell C. Sildenafil an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction . Int J Impot Res. 8:1996;47-52.
33. Boolell M., Gepi-Attee S., Gingell J.C., Allen M.J. Sildenafil, a novel oral therapy for male erectile dysfunction. Br J Urol. 78:1996;257-261.
34. Wallis R.M., Corbin J.D., Francis S.H., Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 83:(suppl):1999;3C-12C.
35. Küthe A, Wiedenroth A, Stief CG, Mägert H-J, Ückert S, Forssmann W-G, Jonas U. Identification of 13 phosphodiesterase isoforms in human cavernous tissue. (Abstr.) Eur Urol 1999;35(suppl 2):101.
36. Meacci E., Taira M., Moos J.R.M., Smith C.J., Movesesian A., Degerman E., Belfrage P., Manganiello V. Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc Natl Acad Sci USA. 89:1992;3721-3725.
37. Chuang A.T., Strauss J.D., Murphy R.A., Steers W.D. Sildenafil, a type-5 cGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J Urol. 160:1998;257-261.
38. Carter A.J., Ballard S.A., Naylor A.M. Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile function in the anesthetized dog. J Urol. 160:1998;242-246.
39. Jeremy J.Y., Ballard S.A., Naylor A.M., Miller M.A.W., Angelini G.D. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol. 79:1997;958-963.
40. Ückert S., Becker A.J., Stief C.G., Truss M.C., Harringer W., Forssmann W.-G., Jonas U. Effects of sildenafil on cyclic AMP and cyclic GMP levels in isolated human cavernous and cardiac tissue. Urology. 55:2000;146-150.